Longeveron Granted EMA SME Designation, Cuts Fees and Boosts 89% Approval Odds
LGVN•Longeveron was granted SME status by the EMA, entitling it to scientific advice, protocol assistance and reduced administrative fees during clinical development of its MSC therapy laromestrocel. EMA data show SME designation raised marketing authorization success rates to 89% in 2020, potentially accelerating regulatory approval.
1. Longeveron Receives EMA SME Status
On June 9, 2026, Longeveron secured Small or Medium-sized Enterprise (SME) designation from the European Medicines Agency, recognizing the company as a small clinical-stage biotechnology entity in Europe. This formal status enables dedicated regulatory interactions and tailored support throughout its product development lifecycle.
2. Enhanced Regulatory Support and Cost Savings
SME designation grants Longeveron access to scientific advice, protocol assistance and early dialogue with EMA multidisciplinary teams, designed to streamline trial design and mitigate approval delays. The company will also benefit from reduced administrative fees on applications and procedures during its clinical development of laromestrocel.
3. Historical Outcomes for EMA SME Designees
EMA statistics show that SME designation more than doubled marketing authorization success rates, reaching 89% for human medicines in 2020, while SMEs accounted for nearly 20% of authorized therapies and over 40% of PRIME priority medicines. These metrics suggest accelerated patient access and a higher likelihood of regulatory approval for Longeveron’s therapy pipeline.
